0L49 Stock Chart & Stats
$3.68
$0.80(21.84%)
At close: 4:00 PM EDT
$3.68
$0.80(21.84%)
Day’s Range― - ―
52-Week Range$3.59 - $10.32
Previous CloseN/A
Volume11.29K
Average Volume (3M)314.00
Market Cap
$48.11M
Enterprise Value-$4.09
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$1.95M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 11, 2026EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding9,949,609
10 Day Avg. Volume423
30 Day Avg. Volume314
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.50Price Target Upside375.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.85
Revenue Forecast (FY)$1.17M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetSCYNEXIS’s very low debt-to-equity (~0.03) provides durable financial flexibility to fund R&D and withstand operating swings without large interest burdens. This reduces refinancing risk, supports selective partnering or milestone-driven investments, and preserves strategic optionality over months.
Pipeline Advancement — SCY-770 Phase 1Initiating Phase 1 for SCY-770 marks a structural pipeline expansion beyond antifungals into ADPKD, addressing a defined ~140k U.S. patient population. A successful proof-of-concept would materially diversify revenue potential and reduce reliance on a single approved product over the medium term.
Partner-based Commercialization ModelRelying on partners for ex-U.S. commercialization and licensing/milestone revenue lowers fixed commercial costs and capital intensity. This model can generate non-dilutive milestone and royalty cashflows and lets SCYNEXIS focus R&D resources, supporting more sustainable capital deployment over time.
Bears Say
Negative Cash Flow / Cash ConsumptionPersistent negative operating and free cash flow (~-$13.3M TTM) means the company cannot self-fund its programs and will likely need external financing or partner funding. Over months this raises execution risk, can delay development timelines, and increases reliance on dilution or deal-dependent financing.
Volatile, Negative ProfitabilityLarge TTM losses and volatile historical profitability (profit spike in 2023 then reversion to losses) indicate inconsistent revenue and weak margin sustainability. This undermines internal reinvestment capacity and makes long-term planning and forecasting for operations and R&D funding less reliable.
Potential Equity Overhang / Dilution RiskApprovals expanding share authorization, a large resale registration and added incentive shares create a durable overhang risk: necessary for financing or compensation but likely to increase share supply over time, diluting per-share economics and complicating capital-raise dynamics over months.
SCYNEXIS News
0L49 FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest share price was $3.59 and its highest was $10.32 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $48.11M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 11, 2026 which is in 89 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $1.137.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.61.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,949,609 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.63 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -9.528%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in GB:0L49
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (375.54% Upside)
$17.50 (375.54% Upside)
Blogger Sentiment
Bullish
GB:0L49 Sentiment 100%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.52%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
0L49 Stock 12 Month Forecast
Average Price Target
$17.50
▲(375.54% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―